Association of Pharmacist Interventions With Adverse Drug Events and Potential Adverse Drug Events
- PMID: 38973415
- DOI: 10.1002/pds.5853
Association of Pharmacist Interventions With Adverse Drug Events and Potential Adverse Drug Events
Abstract
Background: Adverse drug events (ADEs) are a frequent cause of injury in patients. Our aim was to assess whether pharmacist interventions compared with no pharmacist intervention results in reduced ADEs and potential adverse drug events (PADEs).
Methods: We searched MEDLINE, Embase, and two other databases through September 19, 2022 for any RCT assessing the effect of a pharmacist intervention compared with no pharmacist intervention and reporting on ADEs or PADEs. The risk of bias was assessed using the Cochrane tool for RCTs. A random-effects model was used to pool summary results from individual RCTs.
Results: Fifteen RCTs met the inclusion criteria. The pooled results showed a statistically significant reduction in ADE associated with pharmacist intervention compared with no pharmacist intervention (RR = 0.86; [95% CI 0.80-0.94]; p = 0.0005) but not for PADEs (RR = 0.79; [95% CI 0.47-1.32]; p = 0.37). The heterogeneity was insignificant (I2 = 0%) for ADEs and substantial (I2 = 77%) for PADEs. Patients receiving a pharmacist intervention were 14% less likely for ADE than those who did not receive a pharmacist intervention. The estimated number of patients needed to prevent one ADE across all patient locations was 33.
Conclusions: To our knowledge, this is the first systematic review and meta-analysis of RCTs seeking to understand the association of pharmacist interventions with ADEs and PADEs. The risk of having an ADE is reduced by a seventh for patients receiving a pharmacist care intervention versus no such intervention. The estimated number of patients needed to be followed across all patient locations to prevent one preventable ADE across all patient locations is 33.
Keywords: ADEs; PADES; drug safety; pharmacist interventions.
© 2024 John Wiley & Sons Ltd.
References
-
- D. S. Budnitz, M. C. Lovegrove, N. Shehab, and C. L. Richards, “Emergency Hospitalizations for Adverse Drug Events in Older Americans,” New England Journal of Medicine 365, no. 21 (2011): 2002–2012.
-
- H. Aljadhey, M. A. Mahmoud, Y. Ahmed, et al., “Incidence of Adverse Drug Events in Public and Private Hospitals in Riyadh, Saudi Arabia: The (ADESA) Prospective Cohort Study,” BMJ Open 6, no. 7 (2016): e010831.
-
- D. W. Bates, D. J. Cullen, N. Laird, et al., “Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention,” Journal of the American Medical Association 274, no. 1 (1995): 29–34.
-
- D. W. Bates, L. L. Leape, and S. Petrycki, “Incidence and Preventability of Adverse Drug Events in Hospitalized Adults,” Journal of General Internal Medicine 8 (1993): 8289–8294.
-
- L. L. Leape, D. J. Cullen, M. D. Clapp, et al., “Pharmacist Participation on Physician Rounds and Adverse Drug Events in the Intensive Care Unit,” Journal of the American Medical Association 282, no. 3 (1999): 267–270.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
